MLN2238, a proteasome inhibitor, induces caspase-dependent cell death, cell cycle arrest, and potentiates the cytotoxic activity of chemotherapy agents in rituximab-chemotherapy-sensitive or rituximab-chemotherapy-resistant B-cell lymphoma preclinic
about
Next-generation proteasome inhibitor MLN9708 sensitizes breast cancer cells to doxorubicin-induced apoptosisPostulated mechanisms of resistance of B-cell non-Hodgkin lymphoma to rituximab treatment regimens: strategies to overcome resistance.The preclinical discovery of rituximab for the treatment of non-Hodgkin's lymphoma.The proteasome and proteasome inhibitors in multiple myeloma.A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment.
P2860
MLN2238, a proteasome inhibitor, induces caspase-dependent cell death, cell cycle arrest, and potentiates the cytotoxic activity of chemotherapy agents in rituximab-chemotherapy-sensitive or rituximab-chemotherapy-resistant B-cell lymphoma preclinic
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
MLN2238, a proteasome inhibito ...... tant B-cell lymphoma preclinic
@en
MLN2238, a proteasome inhibito ...... tant B-cell lymphoma preclinic
@nl
type
label
MLN2238, a proteasome inhibito ...... tant B-cell lymphoma preclinic
@en
MLN2238, a proteasome inhibito ...... tant B-cell lymphoma preclinic
@nl
prefLabel
MLN2238, a proteasome inhibito ...... tant B-cell lymphoma preclinic
@en
MLN2238, a proteasome inhibito ...... tant B-cell lymphoma preclinic
@nl
P2093
P2860
P1433
P1476
MLN2238, a proteasome inhibito ...... tant B-cell lymphoma preclinic
@en
P2093
Cory Mavis
Francisco J Hernandez-Ilizaliturri
George Deeb
John Gibbs
Joseph J Skitzki
Myron S Czuczman
Natalie M Czuczman
Ritesh Patil
P2860
P304
P356
10.1097/CAD.0000000000000008
P577
2013-11-01T00:00:00Z